Encephalitis, Meningitis
Conditions
Keywords
metagenomic next-generation sequencing, microbiological diagnosis, bacterial infections, viral infections, fungal infections, parasitic infections
Brief summary
This study aims to use a clinically validated metagenomic next-generation sequencing (mNGS) assay to provide a demonstration of precision medicine for diagnosis of acute infectious disease in hospitalized patients. From June 2016 to June 2017, 200 patients will be enrolled from multiple hospitals in California and outside of California. Patients will be evaluated to determine the impact on the mNGS assay on diagnostic yield, hospital costs and clinical outcomes.
Detailed description
This study aims to use a clinically validated metagenomic next-generation sequencing (mNGS) assay to provide a demonstration of precision medicine for diagnosis of acute infectious disease in hospitalized patients, with the goal of directly impacting clinical care and improving patient mortality. This diagnostic test has been previously validated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, the University of California, San Francisco Clinical Microbiology Laboratory. From June 2016 to June 2017, investigators will prospectively enroll 200 patients from multiple hospitals in California (University of California, San Francisco; University of California, Los Angeles; University of California, Davis; Children's Hospital Los Angeles) and outside California (Children's National Medical Center, Children's Hospital Colorado, St. Jude Children's Research Hospital) for mNGS testing, and evaluate the impact on the assay on diagnostic yield, hospital costs and clinical outcomes.
Interventions
This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
Sponsors
Study design
Eligibility
Inclusion criteria
Exclusions: * Patients on a 5150 or 5250 psychiatric hold * Prisoners * University of California employees / students or close associates of any of the key personnel on the study * Outpatients and/or patients with chronic illness Inclusion: Demographic Criteria 1. Age: any (no age limit) 2. Language: any (with the use of interpreting services for obtaining consent) For the following, the infectious syndromes include meningitis, encephalitis, fever, sepsis, and pneumonia: Clinical Criteria 1. Hospital admission or transfer with diagnosis of an presumed infectious syndrome or clinical presentation consisting with an infectious syndrome, as defined below: * Meningitis: fever \>38°C and abnormal imaging or CSF pleocytosis (CSF white blood cell count (WBC) \> 5 /mm\^3) +/- stiff neck, +/- headache, +/- seizure * Encephalitis: pleocytosis and at least one of the following: altered mental status, seizures, new onset of focal neurologic findings, abnormal EEG, acute brain abnormalities on neuroimaging 2. No known diagnosis of non-infectious etiology responsible for symptoms 3. Time of enrollment: within 7 days of onset of symptoms, either initial presentation or acute exacerbation of presumed infectious syndrome. Specimen Criteria 1. cerebrospinal fluid available within 7 days of symptom onset AND within 3 days of hospital admission or transfer unless evidence for acute exacerbation as defined by abrupt decline in clinical status, worsening pleocytosis or other laboratory parameters 2. Minimum of 600 microliters (uL) of clinical sample, stored at 4 degrees Celsius (C) no more than 5 days (ideally frozen in -70 degrees Celsius within 24 hours of collection) 3. No more than 3 freeze-thaw cycles
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Number of Cases With at Least One Provider Response | within 1 month of patient enrollment in study | Investigators will evaluate impact of mNGS assay by clinician surveys and Clinical Microbial Sequencing Board (CMSB) feedback and discussion as measured by at least 1 provider response per case. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Outcomes: Time From Cerebrospinal Fluid Collection to mNGS Results | from admission to 1 month post discharge for each patient during the enrollment period of study | Investigators will review medical records to determine time of initial presentation and measure the time to mNGS results. |
| Clinical Outcomes: Length of Stay | from admission to 1 month post discharge for each patient during the enrollment period of study | Investigators will review medical records to determine length of stay including discharge to rehab facilities. |
| Clinical Outcomes: Final Diagnosis Category | from admission to time of final case review (1 month post discharge or up to one year) | Investigators will review medical records to determine final diagnosis after all diagnostic testing has been performed including metagenomic Next-Gen sequencing and autopsy where applicable. |
| Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens | from admission to 1 month post discharge for each patient during the enrollment period of study | mNGS findings were compared to conventional testing for concordance. Conventional testing included both tests that were ordered as part of each patients workup and those order to confirm mNGS findings on cerebrospinal fluid (CSF). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Patients Enrolled for mNGS Testing Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).
mNGS for pathogen detection: This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples. | 204 |
| Total | 204 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 6 |
| Overall Study | Withdrawal by Subject | 4 |
Baseline characteristics
| Characteristic | Patients Enrolled for mNGS Testing |
|---|---|
| Age, Categorical <=18 years | 45 Participants |
| Age, Categorical >=65 years | 35 Participants |
| Age, Categorical Between 18 and 65 years | 124 Participants |
| Age, Continuous | 39.6 years STANDARD_DEVIATION 22.5 |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 17 Participants |
| Race (NIH/OMB) Black or African American | 13 Participants |
| Race (NIH/OMB) More than one race | 42 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 13 Participants |
| Race (NIH/OMB) White | 118 Participants |
| Region of Enrollment United States | 204 participants |
| Sex: Female, Male Female | 90 Participants |
| Sex: Female, Male Male | 114 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 23 / 204 |
| other Total, other adverse events | 0 / 204 |
| serious Total, serious adverse events | 0 / 204 |
Outcome results
Total Number of Cases With at Least One Provider Response
Investigators will evaluate impact of mNGS assay by clinician surveys and Clinical Microbial Sequencing Board (CMSB) feedback and discussion as measured by at least 1 provider response per case.
Time frame: within 1 month of patient enrollment in study
Population: Treating teams for 204 included patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pre mNGS Result Feedback From Providers | Total Number of Cases With at Least One Provider Response | 98 cases |
| Post mNGS Results Feedback From Providers | Total Number of Cases With at Least One Provider Response | 58 cases |
Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens
mNGS findings were compared to conventional testing for concordance. Conventional testing included both tests that were ordered as part of each patients workup and those order to confirm mNGS findings on cerebrospinal fluid (CSF).
Time frame: from admission to 1 month post discharge for each patient during the enrollment period of study
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Pre mNGS Result Feedback From Providers | Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens | 16 Participants |
| Post mNGS Results Feedback From Providers | Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens | 174 Participants |
| Neoplastic | Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens | 9 Participants |
| Post Infectious | Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens | 1 Participants |
| Toxic Metabolic | Clinical Outcomes: Concordance of mNGS With Other Molecular Testing on Cerebrospinal Fluid Pathogens | 4 Participants |
Clinical Outcomes: Final Diagnosis Category
Investigators will review medical records to determine final diagnosis after all diagnostic testing has been performed including metagenomic Next-Gen sequencing and autopsy where applicable.
Time frame: from admission to time of final case review (1 month post discharge or up to one year)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Pre mNGS Result Feedback From Providers | Clinical Outcomes: Final Diagnosis Category | 17 Participants |
| Post mNGS Results Feedback From Providers | Clinical Outcomes: Final Diagnosis Category | 57 Participants |
| Neoplastic | Clinical Outcomes: Final Diagnosis Category | 7 Participants |
| Post Infectious | Clinical Outcomes: Final Diagnosis Category | 3 Participants |
| Toxic Metabolic | Clinical Outcomes: Final Diagnosis Category | 3 Participants |
| Structural | Clinical Outcomes: Final Diagnosis Category | 0 Participants |
| Vascular | Clinical Outcomes: Final Diagnosis Category | 1 Participants |
| Other | Clinical Outcomes: Final Diagnosis Category | 15 Participants |
| Unknown | Clinical Outcomes: Final Diagnosis Category | 101 Participants |
Clinical Outcomes: Length of Stay
Investigators will review medical records to determine length of stay including discharge to rehab facilities.
Time frame: from admission to 1 month post discharge for each patient during the enrollment period of study
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pre mNGS Result Feedback From Providers | Clinical Outcomes: Length of Stay | 27.9 days | Standard Deviation 32.5 |
Clinical Outcomes: Time From Cerebrospinal Fluid Collection to mNGS Results
Investigators will review medical records to determine time of initial presentation and measure the time to mNGS results.
Time frame: from admission to 1 month post discharge for each patient during the enrollment period of study
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pre mNGS Result Feedback From Providers | Clinical Outcomes: Time From Cerebrospinal Fluid Collection to mNGS Results | 13.5 days | Standard Deviation 4.8 |